3
ICAP

In a clinical trial, ICAP researchers and colleagues suggest convalescent plasma may improve survival with severe COVID-19.

The study was led by investigators from the Center for Infection and Immunity at Columbia University Mailman School of Public Health; Columbia University Irving Medical Center; ICAP at Columbia University; Instituto Nacional de Infectologia and Hospital Federal dos Servidores do Estado in Rio de Janeiro, Brazil; University of Washington; and New York Blood Center. The results are published in the Journal of Clinical Investigation.

Related Items